← Leaderboards
Ginette Serrero
University Of Maryland Baltimore
$8,224,960
Attributed
$8,224,960
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.1M · FY2007–22$2.5M$1.9M$1.3M$625K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$8,224,960 · 11
By mechanism
R44$6,504,218 · 4
R01$901,617 · 1
R43$680,348 · 5
R03$138,777 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Phuoc T. Tran$8,297,853
- Miriam K Laufer$32,646,632
Others in their field
Top investigators on “Biological”
- David Heimbrook · Leidos Biomedical Research, Inc.$731,505,112
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Lawrence Corey · Fred Hutchinson Cancer Center$543,202,300
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$480,487,534
- Tracy L Nolen · Research Triangle Institute$474,487,152
Research focus
BiologicalSerumGrowthTumorTumorigenesisSmall Business Innovation Research GrantAutocrineTissuesCancer CellMalignant NeoplasmsMalignant Breast NeoplasmLiquid SubstanceCessation Of LifeRecurrenceEnrollmentBaseGlycoproteinsGrowth FactorMonitorBlood SpecimenIn VivoOverexpressionPgrn GeneDiagnostic Tests
Grant awards (21)
Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer$826,939
R44 · FY2022 · CA · contact PI
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer$70,818
R44 · FY2022 · CA · contact PI
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer$141,660
R44 · FY2021 · CA · contact PI
Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer$1,062,115
R44 · FY2020 · CA · contact PI
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer$1,101,350
R44 · FY2018 · CA · contact PI
Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies$833,374
R44 · FY2018 · CA · contact PI
Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer$159,365
R44 · FY2018 · CA · contact PI
Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies$1,154,726
R44 · FY2017 · CA · contact PI
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer$152,589
R43 · FY2017 · CA · contact PI
Granulin specific monoclonal antibodies to investigate their expression and role$69,040
R03 · FY2014 · NS · contact PI
Granulin specific monoclonal antibodies to investigate their expression and role$69,737
R03 · FY2013 · NS · contact PI
Targeted Therapy for Non Small Cell Lung Carcinoma: In vivo Feasibility Studies$193,879
R43 · FY2012 · CA · contact PI
Novel Targeted Therapy for Breast Cancer$578,078
R44 · FY2011 · CA · contact PI
Serum GP88 biomarker as a surrogate marker for disease progression in breast canc$113,320
R43 · FY2011 · CA · contact PI
Novel Targeted Therapy for Breast Cancer$575,793
R44 · FY2010 · CA · contact PI
Novel Targeted Therapy for Breast Cancer$120,600
R43 · FY2007 · CA · contact PI
PC CELL DERIVED GROWTH FACTOR IN HUMAN BREAST CANCER$187,425
R01 · FY2004 · CA
Development of a novel serum diagnosis for breast cancer$99,960
R43 · FY2004 · CA
PC CELL DERIVED GROWTH FACTOR IN HUMAN BREAST CANCER$253,575
R01 · FY2003 · CA
PC CELL DERIVED GROWTH FACTOR IN HUMAN BREAST CANCER$233,888
R01 · FY2002 · CA
PC CELL DERIVED GROWTH FACTOR IN HUMAN BREAST CANCER$226,729
R01 · FY2001 · CA